Navigation Links
GenVec Announces Dismissal Of Class Action Lawsuit
Date:9/23/2013

GAITHERSBURG, Md., Sept. 23, 2013 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced that the previously disclosed putative class action lawsuit filed against the Company and certain of its current and former officers (the "Defendants") by the law firm of Brower Piven in the United States District Court for the District of Maryland has been dismissed with prejudice. No payment was made by any of the Defendants to the plaintiffs or their counsel in connection with the lawsuit. The Company does not know whether the plaintiffs will file a Notice of Appeal.

"There are no winners when an experimental therapeutic fails in clinical trials, especially for a challenging and underserved indication such as pancreatic cancer.  We are extremely pleased, however, that the Court recognized that the plaintiffs' claims were without merit and granted in full and with prejudice our motion to dismiss," commented Douglas J. Swirsky, President and Chief Executive Officer of GenVec. 

"The favorable resolution of this case is timely as we work to transition GenVec from a capital-intensive, product development company to one focused on the cost efficient creation of value through the licensing of our proprietary vector and cell line technologies," added Mr. Swirsky.

GenVec and the individual defendants are represented by Hogan Lovells US LLP.

About GenVec
GenVec is a biopharmaceutical company working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to leverage its proprietary gene-delivery technologies to address the prevention and treatment of a number of significant human and animal health concerns. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including with respect to the transition of the Company's business focus, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, such as the failure of Novartis to advance GenVec's hearing loss program, including into human clinical trials.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements. Company Contact: Investor Relations Contact:GenVec, Inc.S.A. Noonan Communications Rena CohenSusan A. Noonan(240) 632-5501(212) 966-3650rcohen@genvec.com  susan@sanoonan.com
'/>"/>

SOURCE GenVec, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec Board Restructures Operations and Withdraws Plan of Dissolution
2. GenVec Reports Fourth Quarter And 2012 Year-End Financial Results
3. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
4. GenVec to Present at 25th Annual ROTH Conference
5. GenVec Reports Third Quarter 2012 Financial Results
6. GenVec Reports Second Quarter 2012 Financial Results
7. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
8. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
9. GenVec Reports Inducement Award
10. GenVec Appoints Cynthia Collins as President and CEO
11. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):